2 companies
UCB
Market Cap: €49.7b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€261.00
7D
2.7%
1Y
62.6%
argenx
Market Cap: €47.5b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€763.20
7D
6.3%
1Y
48.7%